Art. -Nr.: HY-N0701

(-)-Asarinin

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

(-)-Asarinin is a tetrahydrofurofurano lignan with various biological activities. (-)-Asarinin induces apoptosis in cancer cells. (-)-Asarinin promotes mitochondrial ROS accumulation, inhibits the STAT3 signaling pathway and induces apoptosis in precancerous cells. (-)-Asarinin is a Src family kinase inhibitor that suppresses mast cell activation. (-)-Asarinin is a non-competitive Δ5-desaturase inhibitor with a K_i of 0.28 mM. (-)-Asarinin possesses pain relief, anti-viral, anti-allergic and anti-tuberculous bacilli, and anti-tumor effects.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.90%
CAS. Nr.: 133-04-0
Formel: C₂₀H₁₈O₆
Molecular Weight:354.35

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

(-)-Asarinin Chemical Structure

CAS. Nr.: 133-04-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle STAT Isoform-spezifische Produkte anzeigen :

Alle Src Isoform-spezifische Produkte anzeigen :

In Vitro

(-)-Asarinin (20-140 μM; 24-48 h) significantly inhibits the viability of MC cells, a human gastric precancerous lesion cell line, in a dose-dependent manner with an IC₅₀ value of 140 μM, while having no significant inhibitory effect on the viability of normal gastric epithelial cells GES-1^[1].
(-)-Asarinin (80-140 μM; 24-48 h) inhibits the clonogenic ability of MC cells. (-)-Asarinin significantly reduces the migration and invasion abilities of MC cells^[1].
(-)-Asarinin (80-140 μM; 24 h) significantly induces apoptosis and induces G₀/G₁ phase arrest in MC cells. (-)-Asarinin downregulates the expression of cell cycle-related proteins cyclin E1 and cyclin E2 and upregulates the expression of apoptosis - related proteins cleaved caspase 3 and cleaved PARP in MC cells^[1].
(-)-Asarinin (80-140 μM; 24 h) causes mitochondrial damage, reduces mitochondrial membrane potential, decreases ATP production, and increases mitochondrial ROS accumulation in MC cells^[1].
(-)-Asarinin (80-140 μM;) inhibits the expression of STAT3-pathway-related proteins p-STAT3, Bcl-2, and cyclin D1 in MC cells in the STAT3 pathway-related experiments^[1].
(-)-Asarinin (0-90 μM; 48h) induces apoptotic cell death and activates caspase-3, caspase-8, and caspase-9 in human ovarian cancer cells (A2780 and SKOV3)^[2].
(-)-Asarinin (25 μM; for 30 min) significantly reduces the calcium flux in sensitized LAD2 cells in the calcium mobilization assay^[3]. (-)-Asarinin (50 μM; for 20 min) significantly inhibits the release of β - hexosaminidase in sensitized LAD2 cells in the β-hexosaminidase release assay, with an IC₅₀ value of 35.26 μM^[3].
(-)-Asarinin (50 μM; for 20 min) significantly inhibits the release of histamine in sensitized LAD2 cells in the histamine release assay^[3].
(-)-Asarinin significantly reduces the concentrations of TNF- α, MCP-1, IL-4, and IL-5 in sensitized LAD2 cells in the cytokine release assay^[3].
(-)-Asarinin (100 μM; 6 h) inhibits the phosphorylation of Src family kinases such as Lyn and Fyn and downregulates the phosphorylation levels of downstream signals such as PLC-γ1, p38α, and Akt in LAD2 cells in the phosphorylated kinase analysis experiment^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Methylnitronitrosoguanidine-induced malignant transformation of human gastric epithelial cell strain, MC cells
Concentration:

20 μM, 140 μM, 60 μM, 80 μM, 100 μM, 120 μM, 140 μM
Incubation Time:

24 h, 48 h
Result:

Significantly inhibited the viability of MC cells in a dose-dependent manner.

Cell Invasion Assay^[1]

Cell Line:

MC cells
Concentration:

80 μM, 140 μM
Incubation Time:

24 h, 48 h
Result:

At 80 μM, significantly inhibited the migration and invasion of MC cells. At 140 μM, not only significantly inhibited the migration and invasion but also induced apoptosis.

Cell Cycle Analysis^[1]

Cell Line:

MC cells
Concentration:

80 μM, 140 μM
Incubation Time:

24 h
Result:

Induced G₀/G₁ phase arrest, downregulated the expression of cyclin E1 and cyclin E2, and upregulated the expression of cleaved caspase 3 and cleaved PARP.

Apoptosis Analysis^[2]

Cell Line:

A2780, SKOV3 cells
Concentration:

20 μM, 30 μM, 40 μM, 60 μM, 80 μM, 90 μM
Incubation Time:

48 h
Result:

Increased the fractionation of nuclei accumulated at Sub G1 in A2780 and SKOV3 cells, but did not induce cell cycle arrest.
Induced apoptotic cell death.
Activated caspase-3, caspase-8, and caspase-9.

Apoptosis Analysis^[3]

Cell Line:

LAD2 cells
Concentration:

100 μM
Incubation Time:

6 h
Result:

Inhibited the phosphorylation of Lyn, Fyn and other Src family kinases, and downregulated the phosphorylation levels of PLC-γ1, p38α, Akt, and other downstream signals.

In Vivo

(-)-Asarinin (5-20 mg/kg; gavage; once daily; 16 weeks) improves the morphology of gastric mucosal glands, alleviate intestinal metaplasia, inhibit the STAT3 pathway, promote ROS accumulation, and induce apoptosis of gastric mucosal cells in the N-Nitroso-N-methylurea (MNU) (HY-34758)-induced mouse model of gastric precancerous lesions^[1].
(-)-Asarinin (5.0 mg/kg; oral administration; before intranasal OVA challenge) significantly inhibits the allergic reaction, reduces paw swelling and Evans blue exudation in mice, and decreases the degree of mast cell degranulation in the skin in the OVA-induced passive cutaneous anaphylaxis mouse model^[3].
(-)-Asarinin (2.50 mg/kg; oral administration) reduces the concentrations of histamine, TNF-α, MCP-1, IL-4, and IL-5 in the serum of mice in the OVA - induced systemic anaphylaxis mouse model<^[3].
(-)-Asarinin (5.0 mg/kg; oral administration; once daily; from day 21-28) significantly inhibits the scratching and sneezing responses of mice, reduces the concentrations of histamine, total IgE, and IL-4 in the serum of mice, and alleviates the inflammatory infiltration and thickening of the nasal mucosa in the OVA-induced allergic rhinitis mouse model^[3].
(-)-Asarinin (2.5 mg/kg, 5.0 mg/kg, 10 mg/kg; oral administration) inhibits paw swelling and Evans blue exudation in mice and reduces the concentrations of histamine, TNF-α, MCP-1, and IL-8 in the serum in the C48/80-induced allergic reaction mouse model^[3].
C57BL/6 mice (male, 18-22 g), OVA-induced passive cutaneous anaphylaxis model³ 5.0 mg/kg Oral administration Significantly suppressed passive cutaneous anaphylaxis (PCA) in mice, reduced the degree of swelling and Evens blue exudation of mice paw, and decreased the degree of degranulation of MCs in skin. C57BL/6 mice (male, 18-22 g), OVA-induced passive cutaneous anaphylaxis model³ 2.50 mg/kg Oral administration Significantly reduced the concentration of histamine, TNF-α, MCP-1, IL-4 and IL-5 in mice serum. C57BL/6 mice (male, 18-22 g), OVA-induced passive cutaneous anaphylaxis model³ 5.0 mg/kg Oral administration, once daily, from day 21 - 28 Significantly inhibited the scratching and sneezing response of mice, reduced the concentration of histamine, total IgE, and IL - 4 in mice serum, and attenuated the inflammatory infiltrates and nasal mucosa incrassation in the AR mice. C57BL/6 mice (male, 18-22 g), C48/80-induced allergic reaction model³ 2.5 mg/kg, 5.0 mg/kg, 10 mg/kg Oral administration Reduced C48/80-induced paw swelling and Evens blue exudation, and decreased the concentration of histamine, TNF-α, MCP-1 and IL-8 in mice serum.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Animal Model: SPF-grade BALB/c mice (male and female, 18-20 g, 4-week-old), established by administration of carcinogenic agent MNU^[1]
Dosage:

20 mg/kg, 5 mg/kg
Administration:

Gavage, once daily, 16 weeks
Result:

Reversed the deterioration of the gastric mucosal glands' morphology, reduced the severity of intestinal metaplasia, promoted ROS accumulation, inhibited the STAT3 pathway, and induced apoptosis in the gastric mucosa of GPL mice.

Animal Model:

C57BL/6 mice (male, 18-22 g), OVA-induced passive cutaneous anaphylaxis model^[3]
Dosage:

5.0 mg/kg
Administration:

Oral administration
Result:

Significantly suppressed passive cutaneous anaphylaxis (PCA) in mice, reduced the degree of swelling and Evens blue exudation of mice paw, and decreased the degree of degranulation of MCs in skin.

Animal Model:

C57BL/6 mice (male, 18-22 g), OVA-induced passive cutaneous anaphylaxis model^[3]
Dosage:

5 mg/kg
Administration:

Oral administration, once daily, from day 21-28
Result:

Significantly inhibited the scratching and sneezing response of mice, reduced the concentration of histamine, total IgE, and IL - 4 in mice serum, and attenuated the inflammatory infiltrates and nasal mucosa incrassation in the AR mice.

Animal Model:

C57BL/6 mice (male, 18-22 g), OVA-induced passive cutaneous anaphylaxis model³
Dosage:

2.50 mg/kg
Administration:

Oral administration
Result:

Significantly reduced the concentration of histamine, TNF-α, MCP-1, IL-4 and IL-5 in mice serum.

Animal Model:

C57BL/6 mice (male, 18-22 g), C48/80-induced allergic reaction model³
Dosage:

2.5 mg/kg, 5.0 mg/kg, 10 mg/kg
Administration:

Oral administration
Result:

Reduced C48/80-induced paw swelling and Evens blue exudation, and decreased the concentration of histamine, TNF-α, MCP-1 and IL-8 in mice serum.

Chemical Information

CAS. Nr. 133-04-0
Appearance Solid
Molecular Weight 354.35
Formel C₂₀H₁₈O₆
Color White to off-white
SMILES

[H][C@]12[C@](CO[C@@H]2C3=CC=C(OCO4)C4=C3)([H])[C@H](C5=CC=C(OCO6)C6=C5)OC1
Structure Classification
- Phenylpropanoids
- Lignans
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

bioRxiv

2026 Jan 28.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (282.21 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8221 mL

14.1103 mL

28.2207 mL

5 mM

0.5644 mL

2.8221 mL

5.6441 mL

10 mM

0.2822 mL

1.4110 mL

2.8221 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (7.06 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2.5 mg/mL.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.06 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (290 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zhao M, et al. (-)-Asarinin alleviates gastric precancerous lesions by promoting mitochondrial ROS accumulation and inhibiting the STAT3 signaling pathway. Phytomedicine. 2024 Apr;126:155348. [Content Brief]

[2]. Jeong M, et al. (-)-Asarinin from the Roots of Asarum sieboldii Induces Apoptotic Cell Death via Caspase Activation in Human Ovarian Cancer Cells. Molecules. 2018 Jul 25;23(8):1849. [Content Brief]

[3]. Hou Y, et al. (-)-Asarinin inhibits mast cells activation as a Src family kinase inhibitor. Int J Biochem Cell Biol. 2020 Apr;121:105701. [Content Brief]

[4]. Sakayu Shimizu, et al. Inhibition of Δ5-desaturase in polyunsaturated fatty acid biosynthesis by (−)-asarinin and (−)-epiasarinin. Phytochemistry. Volume 31, Issue 3, March 1992, Pages 757-760.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.8221 mL	14.1103 mL	28.2207 mL	70.5517 mL
	5 mM	0.5644 mL	2.8221 mL	5.6441 mL	14.1103 mL
	10 mM	0.2822 mL	1.4110 mL	2.8221 mL	7.0552 mL
	15 mM	0.1881 mL	0.9407 mL	1.8814 mL	4.7034 mL
	20 mM	0.1411 mL	0.7055 mL	1.4110 mL	3.5276 mL
	25 mM	0.1129 mL	0.5644 mL	1.1288 mL	2.8221 mL
	30 mM	0.0941 mL	0.4703 mL	0.9407 mL	2.3517 mL
	40 mM	0.0706 mL	0.3528 mL	0.7055 mL	1.7638 mL
	50 mM	0.0564 mL	0.2822 mL	0.5644 mL	1.4110 mL
	60 mM	0.0470 mL	0.2352 mL	0.4703 mL	1.1759 mL
	80 mM	0.0353 mL	0.1764 mL	0.3528 mL	0.8819 mL
	100 mM	0.0282 mL	0.1411 mL	0.2822 mL	0.7055 mL

Keywords

(-)-Asarinin

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

(-)-Asarinin

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Antibacterial Compound Library

Medicine Food Homology Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) (-)-Asarinin

Alle STAT Isoform-spezifische Produkte anzeigen

Alle Src Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

(-)-Asarinin Related Classifications

HY-N0701 Related Classifications